Aquestive Courts Investors with Needle-Free Epinephrine Film at Key Forum

WARREN, N.J. – July 07, 2026 – Next week, the management of Aquestive Therapeutics will step into a series of crucial one-on-one meetings at the Leerink Partners Therapeutics Forum, an influential gathering of healthcare investors and analysts. While the company's participation was announced via a standard press release, the timing is anything but routine. Aquestive is not just attending another conference; it is making a strategic pitch for its future at a moment when its most promising asset, a novel needle-free treatment for anaphylaxis, approaches the regulatory finish line.

With a PDUFA target action date of January 31, 2026, for its lead candidate, Anaphylm™, the company is at a critical inflection point. These closed-door meetings provide a platform to translate years of clinical development and technological innovation into a compelling investment narrative, one that could secure the capital needed for a successful commercial launch and solidify its position as a disruptor in drug delivery.

A New Frontier in Anaphylaxis Treatment

For decades, the standard of care for severe allergic reactions has been the epinephrine autoinjector, a device synonymous with names like EpiPen. Despite their life-saving function, autoinjectors are plagued by issues of needle-phobia, user error under duress, and portability challenges. Aquestive aims to redefine this market with Anaphylm, a sublingual film designed to deliver epinephrine simply by placing it under the tongue.

Leveraging its proprietary PharmFilm® technology, Anaphylm is a polymer matrix-based epinephrine prodrug about the size of a postage stamp. It dissolves on contact without water, allowing the medicine to be absorbed directly into the bloodstream. This bypasses the digestive system and could lead to a rapid onset of action. The product’s primary packaging is the size of a credit card, designed for discreet portability and stability against environmental factors—a stark contrast to bulky autoinjectors.

The competitive landscape has recently intensified. While Aquestive will compete with established autoinjectors from Viatris and Kaléo, it also faces a new needle-free rival in ARS Pharmaceuticals' Neffy, an epinephrine nasal spray approved in 2024. However, Aquestive’s sublingual film offers a distinct mode of administration that could be advantageous for patients who may have nasal congestion during an allergic reaction or simply prefer an oral option.

Investors will likely be encouraged by positive regulatory signals. The U.S. Food and Drug Administration (FDA) accepted Anaphylm’s New Drug Application (NDA) in June 2025 and, significantly, informed the company that it would not require an Advisory Committee meeting—a step often viewed by analysts as a sign of confidence in the application's data. Aquestive also completed a Type A meeting with the agency in March 2026, a formal meeting to discuss the path forward, keeping the program on track for its PDUFA date.

A Strategic Pitch to Wall Street

The Leerink Partners forum, with its focus on immunology, inflammation, and metabolism, offers a highly specialized and receptive audience for Aquestive's story. The company’s management team will be armed with a compelling financial and clinical narrative. Analyst sentiment is already strong, with a consensus "Strong Buy" rating from seven to ten Wall Street analysts and average 12-month price targets hovering around $9.00 to $10.75—a significant premium over its current trading price of approximately $4.30.

These private meetings are an opportunity to put hard numbers behind that optimism. The company recently strengthened its balance sheet with a $150 million debt refinancing and reported approximately $70 million in cash and cash equivalents at the end of 2024. However, launching a new drug is a capital-intensive endeavor, and securing investor confidence now is paramount to funding marketing, sales force expansion, and manufacturing scale-up. Management will likely emphasize the massive market opportunity and Anaphylm's potential to capture significant share from the multi-billion dollar epinephrine market.

"The company is at a pivotal stage where clinical promise must convert into commercial reality," noted one industry analyst. "The Leerink forum is the perfect venue to articulate how they plan to cross that bridge. Investors will be looking for a clear, fundable strategy for market access and commercial execution."

Beyond Anaphylm: The AdrenaVerse™ Platform

A key part of Aquestive’s pitch will be demonstrating that it is not a single-product company. The innovation behind Anaphylm stems from its broader AdrenaVerse™ platform, a library of more than twenty epinephrine prodrugs designed for various delivery methods. This platform is the engine for a diversified pipeline, most notably with AQST-108, a topical gel being developed for dermatological conditions like alopecia areata.

Aquestive is advancing AQST-108 into a market seeing a wave of new therapies, many of them systemic Janus Kinase (JAK) inhibitors. By developing a topical epinephrine prodrug, the company is pursuing a differentiated approach. A topical treatment could offer localized action at the hair follicle, potentially minimizing the systemic side effects associated with oral medications—a powerful selling point for both patients and physicians.

The program has already shown promise, with a first-in-human study revealing no serious adverse events. Following supportive feedback from the FDA in a pre-IND meeting in late 2024, Aquestive was on track to initiate a Phase 2a trial in mid-2025. This progress in a second, distinct therapeutic area demonstrates the versatility of its technology and provides a hedge against the binary risk of a single drug approval.

The Dual Engine of Development and Manufacturing

Underpinning Aquestive's entire strategy is its unique dual business model. The company operates not only as a developer of its own proprietary products but also as a Contract Development and Manufacturing Organization (CDMO). It is the exclusive manufacturer of four commercialized products marketed by licensees across six continents, all using its proven oral film technologies.

This CDMO business provides a foundational revenue stream that helps offset the high costs and long timelines of internal R&D. It offers a measure of stability that is rare among development-stage pharmaceutical companies, showcasing an established expertise in manufacturing and quality control. This track record provides tangible proof of its ability to produce commercial-grade products, a crucial capability as it prepares to launch Anaphylm. For the investors gathering at the Leerink forum, this hybrid model presents a de-risked opportunity: a company with both a steady manufacturing base and the explosive growth potential of a game-changing new medicine.